Non-small Cell Lung Cancer (NSCLC) in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Explore the Non-Small Cell Lung Cancer (NSCLC) therapeutics market across the 7MM with forecasts to 2032. Analyze epidemiology trends, pipeline drugs, immunotherapies, targeted therapies, market growth, competitive landscape, clinical development, and future opportunities shaping the global NSCLC treatment

Report Value Proposition – Why This Matters for You

The Non-Small Cell Lung Cancer (NSCLC) therapeutics market across the seven major markets (7MM) was valued at $24.1 billion in 2022 and is forecast to reach $56.5 billion by 2032, reflecting a CAGR of 8.9% during the forecast period.

This report helps stakeholders understand how advances in immunotherapy, targeted therapies, precision medicine, and pipeline innovation are transforming the treatment landscape for NSCLC. It provides comprehensive analysis of disease epidemiology, patient populations, treatment patterns, competitive dynamics, and future market opportunities.

Supported by GlobalData’s healthcare intelligence, forecasting models, and analyst expertise, the report offers actionable insight into marketed therapies, late-stage pipeline products, clinical development activity, and emerging treatment strategies shaping the future of NSCLC care.

Key Insights in the NSCLC Therapeutics Market

  • The NSCLC therapeutics market across the 7MM was valued at $24.1 billion in 2022.
  • The market is forecast to reach $56.5 billion by 2032.
  • More than 40 pipeline therapies are expected to enter the market during the forecast period.
  • Diagnosed incident NSCLC cases across the 7MM are expected to increase from 514,561 in 2022 to 564,314 by 2032.
  • Immune checkpoint inhibitors continue to drive significant market growth.
  • Precision medicine approaches are expanding through biomarker-driven targeted therapies.
  • Label expansion of currently marketed therapies into earlier treatment settings is expected to support future growth.
  • Second- and third-line treatment settings are forecast to experience strong expansion due to the introduction of differentiated therapies.
  • Biosimilar competition and generic erosion are expected to increase pricing pressure toward the end of the forecast period.
  • Loss of exclusivity for leading therapies such as Tagrisso and Alecensa may impact future market dynamics.

Scope

What You Will Learn

  • NSCLC epidemiology trends and patient population forecasts through 2032
  • Market size forecasts across the seven major pharmaceutical markets (7MM)
  • Current treatment landscape and standard-of-care evolution
  • Immunotherapy and immune checkpoint inhibitor market developments
  • Precision medicine and targeted therapy opportunities
  • Pipeline analysis of emerging Phase III and Phase IIb therapies
  • Clinical trial activity and innovation trends
  • Market drivers, barriers, and competitive dynamics
  • Revenue forecasts, therapy utilization, and treatment adoption patterns
  • Strategic opportunities for pharmaceutical companies and investors

Target Buyers for This Report

This report may support decision-making for:

  • Pharmaceutical and biotechnology companies
  • Oncology and precision medicine teams
  • Business development and licensing professionals
  • Healthcare investors and private equity firms
  • Clinical development and R&D organizations
  • Commercial strategy and market access teams
  • Competitive intelligence professionals
  • Healthcare consulting firms
  • Oncology-focused market research teams
  • Regulatory and policy specialists

How Companies Use This Report

Pharmaceutical companies may use this report to assess future commercial opportunities, evaluate pipeline competition, and identify strategic areas for investment within the NSCLC treatment landscape.

Oncology-focused biotech firms can leverage the analysis to understand evolving treatment paradigms, emerging therapeutic modalities, and unmet patient needs across major global markets.

Business development teams may use the report to identify licensing opportunities, evaluate competitive positioning, and assess the commercial potential of late-stage pipeline assets.

Investors and strategic planners can also use the insights to evaluate market growth potential, innovation trends, and long-term revenue opportunities within the global NSCLC therapeutics sector.

Key Highlights

This report covers the seven major markets (7MM: US, France, Germany, Italy, Spain, the UK, and Japan).

The report provides an overview of the current treatment options, pipeline products in development, as well as current and future R&D trends.

Key topics covered include a strategic competitive assessment of current and future drugs, unmet needs, KOL insights, and implications for the NSCLC market.

The base year of the sales forecast model is 2022, and the forecast period is 2022-2032.

Reasons to Buy

Benchmark Against NSCLC Market Leaders

The report helps benchmark leading marketed therapies, emerging pipeline candidates, treatment adoption trends, and competitive positioning across the NSCLC market.

It also provides comparative insight into clinical development activity, market share opportunities, and evolving treatment strategies, helping organizations better understand future competitive dynamics.

Built on Trusted GlobalData Oncology Intelligence

Built using proprietary healthcare databases, epidemiology forecasts, pharmaceutical sales intelligence, pricing data, and expert oncology analysis, this report delivers a comprehensive view of the global NSCLC therapeutics market.

Trusted by pharmaceutical companies, healthcare investors, and oncology strategy teams, it provides a reliable foundation for forecasting, market assessment, and strategic decision-making.

Act Now to Capitalize on NSCLC Market Growth

The NSCLC treatment landscape continues to evolve rapidly as immunotherapies, targeted therapies, and precision medicine approaches expand treatment options for patients worldwide. Organizations that closely monitor epidemiology trends, pipeline innovation, and competitive developments will be better positioned to capture emerging opportunities and strengthen their presence in this high-growth oncology market through 2032.

AstraZeneca
Merck
Johnson and Johnson
Roche
Takeda
Xcovery Holdings
Pfizer
Novartis
Daiichi Sankyo
Murus
Array BioPharma
GSK
Bristol-Myers Squibb
Boehringer Ingelheim
Janssen
Eli Lylly
Genmab
Astellas
Mirati Therapeutics
Amgen
WuXi Advanced Therapies
Regeneron
Sanofi
BeiGene
Blueprint Medicines
Bayer
Nuvalent
AbbVie
Gilead Sciences
BionTech
Akeso
Summit Therapeutics
Iovance Biotherapeutics
OncoC4
Arrivent Biopharma
Dizal Pharmaceutical
Taiho Oncology
Shanghai Hengrui Pharmaceuticals
ImmunityBio
Immutep
Revolution Medicines
HUTCHMED (Suzhou)
Innate Pharma
Arcus Biosciences
Guangzhou gloria Biosciences
Incyte
Nuvation Bio
iTeos Therapeutics

Table of Contents

Contents

Abbreviations

Related Reports

Executive Summary

Disease Overview

Overview of Bladder Cancer

Bladder Cancer Market Strength, Weakness, Opportunity, and Threat Analysis

Epidemiology

Diagnosed Incident Cases Both Sexes

Age-Specific Diagnosed Incident Cases

Sex-Specific Diagnosed Incident Cases

Diagnosed Incident Cases by Type, Sex, Age

Diagnosed Incident Cases by Stage at Diagnosis

Diagnosed Incident Cases by Tumor Stage at Diagnosis

Diagnosed Incident Cases of Stage Ta Bladder Cancer by Grade

Diagnosed Incident Cases of Stage of Bladder Cancer by Broad Classification

Diagnosed Incident Cases of Stage of NMIBC by Risk Group

Diagnosed Incident Cases of Bladder Cancer by Mutations and Biomarkers

Five-Year Diagnosed Prevalent Cases of Bladder Cancer

Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Tumor Stage

Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Broad Classification

Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Relapse or Recurrence

Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Treatment

Disease Management

Treatment Guidelines

Treatment Paradigm – First-Line Therapy in Non-Muscle Invasive Bladder Cancer

Treatment Paradigm – First-Line Therapy in Muscle Invasive Bladder Cancer

Treatment Paradigm – Locally Advanced/Metastatic Bladder Cancer

KOL Insight on the Bladder Cancer Treatment Algorithm

Unmet Needs and Opportunities

Unmet Needs in Bladder Cancer

Competitive Landscape Assessment

Pipeline Drugs Overview

Competitive Landscape Methodology

Competitive Assessment – Intravesical Delivered Therapies for NMIBC

Competitive Assessment – Gene Therapies for NMIBC

Competitive Assessment – Antibody-Drug Conjugates

Market Outlook

Bladder Cancer Market Forecast

Bladder Cancer Market Forecast by Class

Bladder Cancer Market Drivers and Barriers

Appendix

Primary Research: KOL Information

Sources Used and Not Used to Forecast Diagnosed Incident Cases

Sources Used to Forecast Diagnosed Incident Cases by Stage at Diagnosis

Sources Used to Forecast Diagnosed Incident Cases by Tumor Stage at Diagnosis

Sources Used to Forecast Diagnosed Incident Cases of Stage Ta Bladder Cancer by Grade

Sources Used to Forecast Diagnosed Incident and Five-Year Diagnosed Prevalent Cases by Broad Classification

Sources Used to Forecast Diagnosed Incident Cases of NMIBC by Risk Group

Sources Used to Forecast Diagnosed Incident Cases by Mutations and Biomarkers

Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases

Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases by Relapse or Recurrence

Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases by Treatment

Sources and Methodology

Epidemiological Forecast Insight

Strengths and Limitations

About the Authors

Bibliography

Contact Us

Non-small Cell Lung Cancer (NSCLC) in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033 standard reports
Currency USD
$17,995

Can be used by individual purchaser only

$53,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Non-small Cell Lung Cancer (NSCLC) in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Non-small Cell Lung Cancer (NSCLC) in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033 in real time.

  • Access a live Non-small Cell Lung Cancer (NSCLC) in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.